Seborrheic dermatitis: topical therapeutics and formulation design
European Journal of Pharmaceutics and Biopharmaceutics · 2023
DOI: 10.1016/j.ejpb.2023.01.023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023. Verfasst von Sean E Mangion und 3 weiteren Autor:innen. Beteiligte Einrichtung: UniSA: Clinical and Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia; Therapeutics Research Centre, Basil He…. Hauptthemen laut MEDLINE: Dermatitis, Seborrheic, Malassezia. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 151 Literaturangaben. Gefördert von: Hospital Research Foundation, National Health and Medical Research Council.
Abstract (Originalsprache)
Seborrheic dermatitis (SD) is a common dermatological disorder with symptoms that include skin flaking, erythema and pruritus. This review discusses the topical products available for treating SD, which target several aspects of disease pathobiology, including cutaneous microbial dysbiosis (driven by Malassezia yeast), inflammation, sebum production and skin barrier disruption. Among the various treatments available, zinc pyrithione (ZnPT) based products that exhibit anti-fungal action are the market leaders. A skin compartment approach is presented here for combining ZnPT exposure information with threshold levels for anti-fungal efficacy and toxicity, overall providing a comprehensive picture of ZnPT therapeutics and safety. While Malassezia yeast on the surface are effectively targeted, yeast residing beyond the superficial follicle may not receive adequate ZnPT for anti-fungal effect forming the basis for skin re-colonisation. Levels entering systemic circulation from topical delivery are well below toxic thresholds, however the elevated zinc levels within the viable epidermis warrants further investigation. Strategies to improve formulation design can be broadly classified as influencing 1) topical delivery, 2) therapeutic bioactivity, 3) skin mildness, and 4) sensory attributes. Successful SD treatment ultimately requires formulations that can balance efficacy, safety, and consumer appeal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UniSA: Clinical and Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia; Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth…
Förderung
- Hospital Research Foundation
- National Health and Medical Research Council
Zitieren
APA
Mangion, S. E., Mackenzie, L., Roberts, M. S., & Holmes, A. M. (2023). Seborrheic dermatitis: topical therapeutics and formulation design. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2023.01.023
Vancouver
Mangion SE, Mackenzie L, Roberts MS, Holmes AM. Seborrheic dermatitis: topical therapeutics and formulation design. European Journal of Pharmaceutics and Biopharmaceutics. 2023. doi:10.1016/j.ejpb.2023.01.023
BibTeX
@article{Mangion2023,
author = {Mangion, Sean E and Mackenzie, Lorraine and Roberts, Michael S and Holmes, Amy M},
title = {Seborrheic dermatitis: topical therapeutics and formulation design},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2023},
doi = {10.1016/j.ejpb.2023.01.023}
}
EUVIMED